SCHEDULE: Dimensional Fund Advisors Discloses 4.7% Stake in Supernus Pharma

Dimensional Fund Advisors LP has reported a 4.7% beneficial ownership stake in Supernus Pharmaceuticals Inc. common stock as of December 31, 2025.

Summary

• Dimensional Fund Advisors LP, an investment adviser, reported beneficial ownership of 2,712,341 shares of Supernus Pharmaceuticals Inc. common stock.
• This ownership represents 4.7% of the class of securities.
• Dimensional Fund Advisors LP holds sole voting power over 2,650,157 shares and sole dispositive power over 2,712,341 shares.
• The reporting person disclaims beneficial ownership, stating that the securities are owned by various funds for which they provide investment advice or management.

Sentiment

Score: 5

Explanation: The filing is a routine beneficial ownership disclosure by an investment adviser, reporting a factual stake in the issuer. It does not contain performance data or forward-looking statements that would typically influence sentiment positively or negatively.

Positives

• The disclosure of a significant stake by a reputable institutional investment adviser like Dimensional Fund Advisors LP may signal institutional confidence in Supernus Pharmaceuticals Inc.

Future Outlook

NA

Industry Context

Dimensional Fund Advisors is a major institutional investment manager. Their filing indicates that funds managed by them hold a significant, though non-controlling, stake in Supernus Pharmaceuticals, a pharmaceutical company. This is a routine disclosure for large institutional investors to report their holdings.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership in Supernus Pharmaceuticals Inc.
• Investment Community: Offers insight into institutional interest in Supernus Pharmaceuticals Inc.

Key Dates

Keywords

Supernus Pharmaceuticals, Dimensional Fund Advisors, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Institutional Ownership